Background:Although vitamin D supplementation is simple, inexpensive, and safe, vitamin D deficiency remains widespread, especially in developing communities. The aim of our study was to assess vitamin D levels among patients with gynecological cancers and compare them with those in patients with benign tumors living in rural and urban areas.Methods: This is a clinical retrospective study covering data analysis from March 2021 to July 2023. A total of 686 patients with uterine or ovarian tumors were analyzed. An electrochemiluminescence immunoassay method was used to assess vitamin D concentrations. Other laboratory blood tests were also performed on the admission day.Results: A significant reduction in vitamin D levels in oncological vs. non-oncological patients (median 23 (17, 33) ng/mL vs. 28 [21, 36] ng/mL,p< 0.001) was observed. The lowest vitamin D concentration was found in patients with ovarian cancer (median 22 (16, 32) ng/mL), followed by those with endometrial cancer and cervical cancer—median 24 (18, 35) ng/mL and 26 (20, 31) ng/mL, respectively). We found no differences in the vitamin D concentration between various histopathological types of ovarian cancers (p= 0.07). No correlation between the vitamin D concentration and age (r = 0.03,p> 0.05) was noted. A negligible negative correlation between vitamin D levels and BMI was observed (r = −0.095,p= 0.03). Additionally, those living in cities had a significantly reduced vitamin D concentration compared to those living in rural areas. No significant differences were demonstrated in vitamin D concentrations between malignant and benign tumors among patients living in rural areas (p= 0.17).Conclusions: Gynecological oncology patients have significantly lower vitamin D levels compared to non-oncological patients. In our patient population, ovarian and endometrial cancers were frequently associated with vitamin D deficiency. While this observation does not establish causation, it highlights the potential value of monitoring vitamin D levels and addressing deficiencies as part of broader cancer prevention and management strategies.
背景：尽管补充维生素D方法简便、成本低廉且安全性高，但维生素D缺乏现象仍普遍存在，在发展中社区尤为突出。本研究旨在评估妇科癌症患者的维生素D水平，并与居住于城乡地区的良性肿瘤患者进行比较。 方法：本研究为临床回顾性分析，涵盖2021年3月至2023年7月的数据。共纳入686例子宫或卵巢肿瘤患者。采用电化学发光免疫分析法检测维生素D浓度，并于入院当日完成其他实验室血液检测。 结果：肿瘤患者较非肿瘤患者的维生素D水平显著降低（中位数23[17,33] ng/mL vs. 28[21,36] ng/mL，p<0.001）。卵巢癌患者的维生素D浓度最低（中位数22[16,32] ng/mL），其次为子宫内膜癌（中位数24[18,35] ng/mL）和宫颈癌患者（中位数26[20,31] ng/mL）。不同组织病理学类型的卵巢癌患者间维生素D浓度无显著差异（p=0.07）。维生素D浓度与年龄无相关性（r=0.03，p>0.05），与体重指数呈微弱负相关（r=-0.095，p=0.03）。此外，城市居民的维生素D浓度显著低于农村居民。农村地区恶性与良性肿瘤患者的维生素D浓度未见显著差异（p=0.17）。 结论：妇科肿瘤患者的维生素D水平显著低于非肿瘤患者。在本研究人群中，卵巢癌和子宫内膜癌常伴随维生素D缺乏。虽然这一发现不能确立因果关系，但提示监测维生素D水平并纠正缺乏状态，可能具有作为癌症综合防治策略组成部分的潜在价值。
Vitamin D Concentration Among Women with Gynecological Cancers
肿瘤(癌症)患者之家